Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Evofosfamide |
| Trade Name | |
| Synonyms | TH-302 |
| Drug Descriptions |
Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (PMID: 32787454, PMID: 31431383). |
| DrugClasses | Chemotherapy - Alkylating 18 |
| CAS Registry Number | 918633-87-1 |
| NCIT ID | C71722 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Balstilimab + Evofosfamide + Zalifrelimab | Balstilimab Evofosfamide Zalifrelimab | 0 | 1 |
| Bevacizumab + Dexamethasone + Evofosfamide | Bevacizumab Dexamethasone Evofosfamide | 0 | 0 |
| Bevacizumab + Evofosfamide | Bevacizumab Evofosfamide | 0 | 2 |
| Dexamethasone + Evofosfamide | Dexamethasone Evofosfamide | 0 | 0 |
| Evofosfamide | Evofosfamide | 0 | 2 |
| Evofosfamide + Ipilimumab | Evofosfamide Ipilimumab | 0 | 1 |
| Evofosfamide + Pazopanib | Evofosfamide Pazopanib | 0 | 1 |
| Evofosfamide + Sorafenib | Evofosfamide Sorafenib | 0 | 1 |